FOCUS on drug failures. Denali Therapeutics‘ experimental drug for Amyotrophic Lateral Sclerosis (ALS) has taken another setback as the drug generated disappointing results in a phase 2/3 trial. The drug known as DNL343 was unable to slow disease progression or increase survival compared to placebo at 24 weeks in the HEALEY ALS study. Mechanistically DNL343 is an activator of eIF2B and it was found to be safe and well tolerated.
Focus Biomolecules can supply DNL343 for research applications. Contact us for more information.
